20Mar 2017

EVALUATION OF T- REGULATORY CELLS IN BREAST CANCER.

  • Professor of Biochemistry, Faculty of Pharmacy for girls, Al-Azhar University.
  • Associate professor of clinical pathology, National Cancer Institute, Cairo University.
  • B.Sc. of pharmaceutical sciences, Faculty of Pharmacy, Cairo University.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Treg cells have an important role in cancer, enabling tumors to elude host anti-tumor immune response.CD4+CD25+ Treg cells constitute 5–10% of peripheral blood CD4+ lymphocytes. Also, CD8+CD25+ cells have been shown a suppressive effect and share phenotypic and functional features with CD4+CD25+ Treg cells. Aim of the work: This work was done to evaluate the frequency of expression of different Treg cells in the peripheral blood of breast cancer patients and to elucidate their impact on clinical and laboratory parameters. Patients and Methods: This study included forty-seven Egyptian breast cancer patients (30 de novo patients and 17 after surgery patients) and13 healthy controls and 18 benign breast patients. They were tested by Flow Cytometry Results:CD4+CD25+ Treg cells were significantly higher in the de novo compared to the healthy controls and in the after-surgery group compared to the healthy controls and benign breast groups (P<0.0001), while CD4+CD25hi were significantly higher in both de novo and after surgery patients as compared to healthy controls (P<0.0001). Conclusion: some Treg cells as CD4+CD25+ cells are predominant in breast cancer patients.

  1. Abo-Elenein A, Elgohary SE, Hashish A and El-Halaby E, Significance of immunoregulatory T cells in different stages of breast cancer patients. Egypt J Immunol., 2008; 15(2): 145-52.
  2. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL and Banham AH, Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse. J ClinOncol., 2006; 24(34): 5373-80.
  3. Baumgartner JM and McCarter MD, Suppressing the suppressor: Role of immunosuppressive regulatory T cells in cancer surgery. Surgical Research Review 2009; 145: 345-50.
  4. Bisikirska B, Colgan J, Luban J, Bluestone JA and Herold KC, TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest. 2005;115: 2904–13.
  5. Chui SY, Morse MA, Doldo T, Osada T, Clay TM, Lyerly HK, Khan S, Gattis A and Hobeika AC, Regulatory and effector T cell subsets and dendritic cells in breast cancer., Journal of Clinical Oncology 2004; 22 (14S): 9697.
  6. Cosmi L, Liotta F, Lazzeri E, Francalanci M, Angeli R, Mazzinghi B, Santarlasci V, Manetti R, Vanini V, Romagnani P, Maggi E, Romagnani S and Annunziato F, Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+ CD25+ regulatory thymocytes. Blood 2003; 102:4107–14.
  7. Erlandsson MC, Ohlsson C, Gustafsson JA, Carlsten H, Role of oestrogen receptors alpha and beta in immune organ development and in oestrogen-mediated effects on thymus. Immunology, 2001: 103:17–25.
  8. Hekim C1, Ilander M1, Yan J2, Michaud E2, Smykla R2, Vähä-Koskela M3, Savola P1, Tähtinen S3, Saikko L4, Hemminki A3, Kovanen PE4, Porkka K1, Lee FY2, Mustjoki SDasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models.Cancer Immunol Res. 2017 Feb;5(2):157-169.
  9. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, Global Cancer Statistics CA. CANCER J CLIN.2011: 61:69–90.
  10. Leong PP, Mohammad R, Ibrahim N, Ithnin H, Abdullah M, Davis WC,Seow HF, Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. Immunology Letters.2006: 102: 229–236.
  11. Liu S, Foulkes WD, Leung S, Gao D, Lau S, Kos Z, Nielsen TO, Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res. 2014 Sep 6;16(5):43.
  12. Maggi E, Cosmi L, Liotta F, Romagnani P, Romagnani S, Annunziato F, Thymicregulatory T cells. Autoimmun Rev., (2005):4: 579–86.
  13. Mahmoud SMA, Paish EC, Powe DG, Macmillan RD, Lee AHS, Ellis IO, Green AR, An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Research and Treatment. 2011: May; 127(1): 99-108.
  14. Meloni F, Morosini M, Solari N, Passadore I, Nascimbene C, Novo M, Ferrari M, Cosentino M, Marino F, Pozzi E, Fietta AM,Foxp3 expressing CD4+ CD25+ and CD8+CD28? T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol.2006: 67:1–12.
  15. Mokhtar N, Gouda I, Adel I, Breast cancer. In Mokhtar, N., Gouda, I., Adel, I. (eds.): Cancer pathology registry, 2003-2004 and time trend analysis 2007: Cairo, NCI, El Sheraa Press. Available online: http://www.nci.cu.edu.eg/ (accessed 26/12/2011).
  16. Mozaffari F, Lindemalm C, Choudhury A, Granstam-Bjo¨rneklett H, Helander H, Lekander M, Mikaelsson E, Nilsson B, Ojutkangas ML, Osterborg A, Bergkvist L, Mellstedt H,NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy. British Journal of Cancer.2007: 97:105–11.
  17. Perez SA, Karamouzis MV, Skarlos DV et al., CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. 2007: Clin. Cancer Res., 13: 2714-2721.
  18. Pinho MB and Barbuto JAM, Systemic alterations in T cell subpopulations of breast cancer patients. Cancer Immunol Res. 2016 January 4 (1 suppl); abstract B096.
  19. Shao B1, Li HP1, DI LJ1, Song GH1, Jiang HF1, Liang X1, Wang CY1, Yan Y1, Lin XL1, Wang LN1, Wan FL1, Yuan YH1, You MNPredictive and prognostic value of monitoring lymphocyte subsets in peripheral blood before and after chemotherapy in patients with metastatic breast cancer.ImmunopharmacolImmunotoxicol. 2017 Feb;39(1):37-44.
  20. Song Q, Ren J, Zhou X, Wang X, Song G, Di L, Yu J, Hobeika A, Morse MA, Yuan Y, Yang H, Lyerly HK, The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion. 2015 Dec 1; 6(38): 41350–41359.
  21. Tsaknaridis L, Spencer L, Culbertson N, Hicks K, LaTocha D, Chou YK, Whitham RH, Bakke A, Jones RE, Offner H, Bourdette DN, Vandenbark AA,Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity. J Neurosci Res,2003:15; 74(2):296-308
  22. Wang Z, Yang B, Liu H, Hu Y, Yang J,  Wu L,  Zhou Z, Jiao S, Regulatory T cells increase in breast cancer and in stage IV breast cancer. Cancer Immunology Immunotherapy.2011: 24 November.
  23. Wilke CM. Wu K, Zhao E, Wang G, Zou W, Prognostic significance of regulatory T cells in tumor International Journal of Cancer. 2010:127(4): 748–58.
  24. Xia Q1, Geng F1, Zhang FF1, Liu CL1, Xu P1, Lu ZZ1, Xie Y1, Sun B1, Wu H1, Yu B1, Kong W1, Yu XH1, Zhang HHCyclophosphamide enhances anti-tumor effects of a fibroblast activation protein ?-based DNA vaccine in tumor-bearing mice with murine breast carcinoma.ImmunopharmacolImmunotoxicol. 2017 Feb;39(1):37-44.
  25. Zhang L, Zhao Y, The regulation of Foxp3 expression in regulatory CD4 (+) CD25 (+) T cells: multiple pathways on the road. J Cell Physiol., 2007: 211(3):590-7.
  26. Zhu S1, Lin J1, Qiao G1, Xu Y2, Zou H3, Differential regulation and function of tumor-infiltrating T cells in different stages of breast cancer patients. Tumour Biol. 2015 Sep;36(10):7907-13.

[Ola Sayed Mohamed Ali, Maha A. El-Taweel, Iman Attia Abdel El-Gawad and Eman Ahmed Gouda. (2017); EVALUATION OF T- REGULATORY CELLS IN BREAST CANCER. Int. J. of Adv. Res. 5 (Mar). 99-107] (ISSN 2320-5407). www.journalijar.com

Maha El-Taweel
Assistant Prof in Clinical Pathology department, National Cancer Institute, Cairo University

DOI:

Article DOI: 10.21474/IJAR01/3491      
DOI URL: http://dx.doi.org/10.21474/IJAR01/3491

Download Full Paper

Download PDF No. of Downloads: 40 | No. of Views: 95